• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于机器学习的列线图用于预测恶性胸腔积液肺癌患者预后的开发与验证

Development and validation of a machine learning-based nomogram for predicting prognosis in lung cancer patients with malignant pleural effusion.

作者信息

Hu Xin, Zhao Shiqiao, Li Yanlun, Heibi Yiluo, Wu Hang, Jiang Yongjie

机构信息

Department of Respiratory and Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

Department of Emergency Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

出版信息

Sci Rep. 2025 Mar 21;15(1):9714. doi: 10.1038/s41598-025-93842-4.

DOI:10.1038/s41598-025-93842-4
PMID:40113952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11926256/
Abstract

Malignant pleural effusion (MPE) is a common complication in patients with advanced lung cancer, significantly impacting their survival rates and quality of life. Effective tools for assessing the prognosis of these patients are urgently needed to enable early intervention. This study retrospectively analyzed patient data from the Affiliated Hospital of North Sichuan Medical College from 2013 to 2021, which served as the training cohort and internal testing cohort. Additionally, three external testing cohorts were introduced: data from Guang'an People's Hospital as cohort 1, data from Dazhou Central Hospital as cohort 2, and data from the Affiliated Hospital of North Sichuan Medical College from January 1, 2023, to December 31, 2023, constituting the temporal external testing cohort. Univariate logistic regression (LR) analysis of clinical variables (P < 0.05) was performed, followed by multivariate LR to identify independent predictors for inclusion in nine machine learning models: Decision Tree (DT), Random Forest (RF), Extreme Gradient Boosting (XGBoost), Elastic Net (Enet), Radial Support Vector Machine (rSVM), Multilayer Perceptron (MLP), LR, Light Gradient Boosting Machine (LightGBM), and K-Nearest Neighbors (KNN). The best-performing model was used to develop a nomogram for patient risk stratification. Three variables-treatment regimen, presence of pericardial effusion, and total pleural effusion volume-were identified as significant predictors in the study. The LR model demonstrated the best performance, achieving area under the curve (AUC) values of 0.885 in the training cohort, 0.954 in the internal testing cohort, and 0.920 in external testing cohort 1. To further validate the model's robustness, the nomogram developed from the LR model was evaluated in two additional validation cohorts: external testing cohort 2 and a temporal external testing cohort. The nomogram achieved AUCs of 0.962 in external testing cohort 2 and 0.949 in the temporal external testing cohort, demonstrating strong predictive accuracy. Calibration curves confirmed excellent model-reality concordance across all cohorts, and decision curve analysis (DCA) revealed superior clinical utility. The nomogram enabled individualized risk quantification and showed significant survival differences between high-risk/very high-risk groups and low-risk/medium-risk groups. This study evaluated nine machine learning models for prognostic prediction in lung cancer patients with MPE, finding that the LR-based model offered the best performance. A nomogram based on this model can effectively stratify patients for prognostic assessment and early intervention.

摘要

恶性胸腔积液(MPE)是晚期肺癌患者常见的并发症,严重影响其生存率和生活质量。迫切需要有效的工具来评估这些患者的预后,以便进行早期干预。本研究回顾性分析了2013年至2021年川北医学院附属医院的患者数据,该数据用作训练队列和内部测试队列。此外,引入了三个外部测试队列:广安人民医院的数据作为队列1,达州中心医院的数据作为队列2,以及川北医学院附属医院2023年1月1日至2023年12月31日的数据,构成时间外部测试队列。对临床变量进行单因素逻辑回归(LR)分析(P<0.05),然后进行多因素LR分析,以确定纳入九个机器学习模型的独立预测因素:决策树(DT)、随机森林(RF)、极端梯度提升(XGBoost)、弹性网络(Enet)、径向支持向量机(rSVM)、多层感知器(MLP)、LR、轻梯度提升机(LightGBM)和K近邻(KNN)。使用表现最佳的模型开发患者风险分层列线图。研究确定了三个变量——治疗方案、心包积液的存在和胸腔积液总量——为显著预测因素。LR模型表现最佳,在训练队列中的曲线下面积(AUC)值为0.885,在内部测试队列中为0.954,在外部测试队列1中为0.920。为了进一步验证模型的稳健性,在另外两个验证队列中评估了从LR模型开发的列线图:外部测试队列2和时间外部测试队列。该列线图在外部测试队列2中的AUC为0.962,在时间外部测试队列中的AUC为0.949,显示出很强的预测准确性。校准曲线证实了所有队列中模型与实际情况的良好一致性,决策曲线分析(DCA)显示出卓越的临床实用性。该列线图能够进行个体化风险量化,并显示出高风险/极高风险组与低风险/中等风险组之间存在显著的生存差异。本研究评估了九个机器学习模型对MPE肺癌患者的预后预测,发现基于LR的模型表现最佳。基于该模型的列线图可以有效地对患者进行分层,用于预后评估和早期干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/ff9bfe49965a/41598_2025_93842_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/39b3d6a571d2/41598_2025_93842_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/84531dc7cef3/41598_2025_93842_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/ff9bfe49965a/41598_2025_93842_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/39b3d6a571d2/41598_2025_93842_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/84531dc7cef3/41598_2025_93842_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538d/11926256/ff9bfe49965a/41598_2025_93842_Fig3_HTML.jpg

相似文献

1
Development and validation of a machine learning-based nomogram for predicting prognosis in lung cancer patients with malignant pleural effusion.基于机器学习的列线图用于预测恶性胸腔积液肺癌患者预后的开发与验证
Sci Rep. 2025 Mar 21;15(1):9714. doi: 10.1038/s41598-025-93842-4.
2
Exploring prognostic precision: a nomogram approach for malignant pleural effusion in lung cancer.探索预后精准度:一种用于肺癌恶性胸腔积液的列线图方法
BMC Cancer. 2025 Feb 10;25(1):227. doi: 10.1186/s12885-025-13632-z.
3
Prediction of STAS in lung adenocarcinoma with nodules ≤ 2 cm using machine learning: a multicenter retrospective study.使用机器学习预测直径≤2 cm的肺腺癌中的STAS:一项多中心回顾性研究
BMC Cancer. 2025 Mar 7;25(1):417. doi: 10.1186/s12885-025-13783-z.
4
Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data.基于常规实验室数据的机器学习模型对恶性胸腔积液进行鉴别诊断的建立与验证。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208632. doi: 10.1177/17534666231208632.
5
Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion.非小细胞肺癌合并恶性胸腔积液患者肌肉减少症的预测模型
BMC Cancer. 2025 Feb 25;25(1):350. doi: 10.1186/s12885-025-13772-2.
6
Derivation and validation of the first web-based nomogram to predict the spontaneous pregnancy after reproductive surgery using machine learning models.首个基于网络的列线图的推导与验证,该列线图利用机器学习模型预测生殖手术后的自然妊娠情况。
Front Endocrinol (Lausanne). 2024 Jul 2;15:1378157. doi: 10.3389/fendo.2024.1378157. eCollection 2024.
7
Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.低社会经济地位的晚期肺癌患者的预后和风险因素评估:模型的建立和验证。
BMC Cancer. 2024 Sep 10;24(1):1128. doi: 10.1186/s12885-024-12863-w.
8
Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.基于机器学习算法和细胞因子的乳腺癌肺转移列线图模型的开发与验证
BMC Cancer. 2025 Apr 14;25(1):692. doi: 10.1186/s12885-025-14101-3.
9
Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation.抗黑色素瘤分化相关基因5抗体阳性、皮肌炎相关间质性肺疾病患者的死亡风险预测:算法开发与验证
J Med Internet Res. 2025 Feb 5;27:e62836. doi: 10.2196/62836.
10
The CMLA score: A novel tool for early prediction of renal replacement therapy in patients with cardiogenic shock.CMLA 评分:一种用于预测心源性休克患者肾脏替代治疗的新工具。
Curr Probl Cardiol. 2024 Dec;49(12):102870. doi: 10.1016/j.cpcardiol.2024.102870. Epub 2024 Sep 27.

本文引用的文献

1
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.恶性胸腔积液中的免疫调节:从微环境到治疗意义
Cancer Cell Int. 2024 Mar 12;24(1):105. doi: 10.1186/s12935-024-03211-w.
2
Cardiac tamponade.心脏压塞。
Nat Rev Dis Primers. 2023 Jul 20;9(1):36. doi: 10.1038/s41572-023-00446-1.
3
Targeted therapy for lung cancer: Beyond EGFR and ALK.肺癌的靶向治疗:超越 EGFR 和 ALK。
Cancer. 2023 Jun 15;129(12):1803-1820. doi: 10.1002/cncr.34757. Epub 2023 Apr 19.
4
Malignant pleural effusion diagnosis and therapy.恶性胸腔积液的诊断与治疗。
Open Life Sci. 2023 Feb 28;18(1):20220575. doi: 10.1515/biol-2022-0575. eCollection 2023.
5
Current status of and progress in the treatment of malignant pleural effusion of lung cancer.肺癌恶性胸腔积液的治疗现状与进展
Front Oncol. 2023 Jan 20;12:961440. doi: 10.3389/fonc.2022.961440. eCollection 2022.
6
Update on the diagnosis and management of malignant pleural effusions.恶性胸腔积液的诊断与管理进展
Respir Med. 2022 May;196:106802. doi: 10.1016/j.rmed.2022.106802. Epub 2022 Mar 9.
7
Targeted therapies for cancer.癌症的靶向治疗。
BMC Med. 2022 Mar 11;20(1):90. doi: 10.1186/s12916-022-02287-3.
8
Evaluation of Efficacy and Safety for Kanglaite Injection in the Control of the Malignant Pleural Effusions via Thoracic Perfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.康莱特注射液经胸腔灌注控制恶性胸腔积液的疗效与安全性评价:一项随机对照试验的系统评价与Meta分析
Front Pharmacol. 2021 Nov 3;12:694129. doi: 10.3389/fphar.2021.694129. eCollection 2021.
9
Advances in Exosome-Based Drug Delivery and Tumor Targeting: From Tissue Distribution to Intracellular Fate.基于外泌体的药物传递和肿瘤靶向的进展:从组织分布到细胞内命运。
Int J Nanomedicine. 2020 Nov 24;15:9355-9371. doi: 10.2147/IJN.S281890. eCollection 2020.
10
Tumor-derived microparticles in tumor immunology and immunotherapy.肿瘤免疫和免疫治疗中的肿瘤衍生微粒。
Eur J Immunol. 2020 Nov;50(11):1653-1662. doi: 10.1002/eji.202048548. Epub 2020 Oct 28.